NeuroSense Therapeutics (NRSN) Short Interest Ratio & Short Volume $1.09 -0.01 (-0.91%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.08 -0.01 (-0.46%) As of 02/21/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NeuroSense Therapeutics Short Interest DataNeuroSense Therapeutics (NRSN) has a short interest of 161,300 shares, representing 1.13% of the float (the number of shares available for trading by the public). This marks a -31.80% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.6, indicating that it would take 0.6 days of the average trading volume of 152,186 shares to cover all short positions.Current Short Interest161,300 sharesPrevious Short Interest236,500 sharesChange Vs. Previous Month-31.80%Dollar Volume Sold Short$179,043.00Short Interest Ratio0.6 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares13,670,000 sharesFloat Size14,240,000 sharesShort Percent of Float1.13%Today's Trading Volume108,040 sharesAverage Trading Volume152,186 sharesToday's Volume Vs. Average71% Short Selling NeuroSense Therapeutics? Sign up to receive the latest short interest report for NeuroSense Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNRSN Short Interest Over TimeNRSN Days to Cover Over TimeNRSN Percentage of Float Shorted Over Time NeuroSense Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/2025161,300 shares $179,043.00 -31.8%1.1%0.6 $1.11 1/15/2025236,500 shares $244,777.50 +18.2%1.7%0.8 $1.04 12/31/2024200,100 shares $240,120.00 -31.1%1.5%0.7 $1.20 12/15/2024290,600 shares $249,916.00 -10.4%2.2%1 $0.86 11/30/2024324,400 shares $317,912.00 +25.7%2.1%1.7 $0.98 11/15/2024258,100 shares $317,463.00 -32.6%1.8%1.1 $1.23 10/31/2024383,000 shares $478,750.00 +62.5%2.6%1.6 $1.25 10/15/2024235,700 shares $225,564.90 -23.3%1.6%0.9 $0.96 9/30/2024307,400 shares $390,398.00 -20.3%2.1%1 $1.27 9/15/2024385,600 shares $520,560.00 -18.1%2.7%1 $1.35 Get the Latest News and Ratings for NRSN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/2024470,700 shares $418,923.00 +236.2%3.3%1.2 $0.89 8/15/2024140,000 shares $103,600.00 +73.7%1.0%0.5 $0.74 7/31/202480,600 shares $61,239.88 -44.8%0.6%0.3 $0.76 7/15/2024146,000 shares $134,918.60 +715.6%1.1%0.6 $0.92 6/30/202417,900 shares $20,048.00 +121.0%0.1%0.1 $1.12 6/15/20248,100 shares $7,857.00 -17.4%0.1%0.1 $0.97 5/31/20249,800 shares $10,584.00 -52.4%0.1%0.1 $1.08 5/15/202420,600 shares $24,678.80 +13.2%0.2%0.1 $1.20 4/30/202418,200 shares $24,570.00 -79.4%0.2%0.1 $1.35 4/15/202488,400 shares $135,252.00 +38.8%0.8%0.3 $1.53 3/31/202463,700 shares $115,934.00 +81.5%0.7%0.2 $1.82 3/15/202435,100 shares $48,438.00 -83.4%0.4%0.1 $1.38 2/29/2024211,400 shares $374,178.00 +42.0%2.3%0.5 $1.77 2/15/2024148,900 shares $198,037.00 +12.7%1.6%0.2 $1.33 1/31/2024132,100 shares $165,125.00 -35.6%1.5%0.2 $1.25 1/15/2024205,200 shares $175,261.32 -17.7%2.3%0.2 $0.85 12/31/2023249,200 shares $195,622.00 +18.7%2.7%0.3 $0.79 12/15/2023210,000 shares $176,631.00 +1.9%2.3%0.2 $0.84 11/30/2023206,100 shares $265,869.00 -11.9%2.3%0.3 $1.29 11/15/2023234,000 shares $120,276.00 +89.3%2.6%1 $0.51 10/31/2023123,600 shares $56,930.16 +182.2%1.4%0.6 $0.46 10/15/202343,800 shares $23,956.67 +91.3%0.5%0.3 $0.55 9/30/202322,900 shares $16,259.00 -3.8%0.3%0.3 $0.71 9/15/202323,800 shares $20,944.00 +9.2%0.3%0.6 $0.88 8/31/202321,800 shares $20,492.00 +77.2%0.2%0.5 $0.94 8/15/202312,300 shares $11,808.00 -37.6%0.1%0.2 $0.96 7/31/202319,700 shares $25,610.00 -53.4%0.3%0.3 $1.30 7/15/202342,300 shares $57,528.00 -38.3%0.6%0.5 $1.36 6/30/202368,600 shares $102,214.00 -12.4%1.0%0.9 $1.49 6/15/202378,300 shares $144,072.00 -38.8%1.2%1 $1.84This Crypto Is Set to Explode in February (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW 5/31/2023127,900 shares $199,524.00 -13.6%1.9%1.9 $1.56 5/15/2023148,000 shares $253,080.00 -1.7%2.2%2.9 $1.71 4/30/2023150,600 shares $304,212.00 -12.0%2.2%2 $2.02 4/15/2023171,100 shares $278,893.00 -8.2%2.5%1.4 $1.63 3/31/2023186,300 shares $320,436.00 -6.1%2.8%0.1 $1.72 3/15/2023198,300 shares $354,957.00 -6.4%3.1%0.1 $1.79 2/28/2023211,800 shares $393,948.00 -10.1%3.1%0.2 $1.86 2/15/2023235,700 shares $393,619.00 +8.2%3.4%0.2 $1.67 1/31/2023217,900 shares $337,745.00 +1,479.0%3.2%0.2 $1.55 1/15/202313,800 shares $18,630.00 -25.0%0.2%0 $1.35 12/30/202218,400 shares $22,448.00 -24.6%0.3%0.7 $1.22 12/15/202224,400 shares $37,332.00 -22.0%0.4%0.8 $1.53 11/30/202231,300 shares $53,836.00 +30.4%0.5%0.9 $1.72 11/15/202224,000 shares $40,800.00 -21.8%0.4%0.6 $1.70 10/31/202230,700 shares $49,120.00 -40.0%0.5%0.8 $1.60 10/15/202251,200 shares $87,552.00 -53.7%0.7%0.7 $1.71 9/30/2022110,500 shares $197,795.00 +269.6%1.6%1.1 $1.79 9/15/202229,900 shares $61,893.00 +13.7%0.4%0 $2.07 8/31/202226,300 shares $51,285.00 -46.8%0.4%0 $1.95 8/15/202249,400 shares $111,150.00 +31.4%0.8%0 $2.25 7/31/202237,600 shares $70,312.00 -36.5%0.6%0 $1.87 7/15/202259,200 shares $121,952.00 -91.8%0.9%0 $2.06 6/30/2022719,900 shares $2.43 million +302.4%11.7%0.2 $3.38 6/15/2022178,900 shares $305,919.00 +1.6%2.9%0.2 $1.71 5/31/2022176,100 shares $248,301.00 +78.8%2.9%0 $1.41 5/15/202298,500 shares $125,095.00 +64.2%1.6%0 $1.27 4/30/202260,000 shares $100,800.00 +26.3%1.0%0 $1.68 4/15/202247,500 shares $95,950.00 -86.3%N/A0 $2.02 3/31/2022347,000 shares $1.38 million +568.6%5.7%0.1 $3.97 3/15/202251,900 shares $72,660.00 +464.1%0.9%0 $1.40 2/28/20229,200 shares $23,920.00 +187.5%0.2%0 $2.60 2/15/20223,200 shares $5,568.00 -38.5%0.1%0 $1.74 1/31/20225,200 shares $10,244.00 -80.4%0.1%0 $1.97 1/15/202226,500 shares $72,875.00 +69.9%0.4%0.1 $2.75 12/31/202115,600 shares $38,376.00 No Change0.3%0 $2.46 NRSN Short Interest - Frequently Asked Questions What is NeuroSense Therapeutics' current short interest? Short interest is the volume of NeuroSense Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 31st, investors have sold 161,300 shares of NRSN short. 1.13% of NeuroSense Therapeutics' shares are currently sold short. Learn More on NeuroSense Therapeutics' current short interest. What is a good short interest ratio for NeuroSense Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NRSN shares currently have a short interest ratio of 1.0. Learn More on NeuroSense Therapeutics's short interest ratio. What is a good short interest percentage for NeuroSense Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.13% of NeuroSense Therapeutics' floating shares are currently sold short. Is NeuroSense Therapeutics' short interest increasing or decreasing? NeuroSense Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 161,300 shares, a decrease of 31.8% from the previous total of 236,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NeuroSense Therapeutics' float size? NeuroSense Therapeutics currently has issued a total of 13,670,000 shares. Some of NeuroSense Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NeuroSense Therapeutics currently has a public float of 14,240,000 shares. How does NeuroSense Therapeutics' short interest compare to its competitors? 1.13% of NeuroSense Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to NeuroSense Therapeutics: Century Therapeutics, Inc. (8.82%), Oncolytics Biotech Inc. (4.15%), bluebird bio, Inc. (26.30%), Prelude Therapeutics Incorporated (14.54%), IO Biotech, Inc. (0.08%), Werewolf Therapeutics, Inc. (5.44%), Immuneering Co. (9.64%), OptiNose, Inc. (3.12%), Kronos Bio, Inc. (2.40%), Achilles Therapeutics plc (0.15%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short NeuroSense Therapeutics stock? Short selling NRSN is an investing strategy that aims to generate trading profit from NeuroSense Therapeutics as its price is falling. NRSN shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NeuroSense Therapeutics? A short squeeze for NeuroSense Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NRSN, which in turn drives the price of the stock up even further. How often is NeuroSense Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NRSN, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies Century Therapeutics Short Interest Data Oncolytics Biotech Short Interest Data bluebird bio Short Interest Data Prelude Therapeutics Short Interest Data IO Biotech Short Interest Data Werewolf Therapeutics Short Interest Data Immuneering Short Interest Data OptiNose Short Interest Data Kronos Bio Short Interest Data Achilles Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NRSN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
